Long-Acting Beta Agonist

Fluticasone-based inhaled corticosteroid treatment substantially changed airway microbiome diversity in patients with COPD, according to new data published in the American Journal of Respiratory and Critical Care Medicine.

COPD maintenance therapy, particularly the combination of a long-acting beta agonist and long-acting muscarinic antagonist, was associated with left atrial size, according to an observational study published in Respiratory Medicine.